P53 in the Clinics

ISBN-13: 9781489992178 / Angielski / Miękka / 2014 / 358 str.

Pierre Hainaut; Magali Olivier; Klas G. Wiman

Opis

This project follows on the success of the book "25 years of p53", published by Springer in 2006. Since this publication, there have been considerable advances on the potential application of p53 into the clinics. The goal of this book is to capture these developments and to appeal to a clinical and medical audience beyond the one which was the primary target of "25 years of p53".

Spis treści

Foreword.- p53 activities and the hallmarks of cancer.- The inheritance of p53.- p53: Guardian of the metabolome.- The p53 family and stem cell biology.- Mutant p53-driven tumorigenesis.- Humanized p53 mouse models.- p53 models for mammary carcinogenesis.- TP53 somatic mutations: Prognostic and predictive value in human cancers.- Assessing TP53 status in human tumors - lessons from breast cancer.- TP53 germline mutations: Genetics of Li-Fraumeni Syndrome.- TP53 gene therapy.- Upstream targets in the p53 pathway.- p53-reactivating molecules as research tools and anti-cancer drugs.- Restoring mutant p53 activity.- p53-immunotherapy of cancer.- Designing p53 trials: a surgical oncologist view.- p53 in the clinic: a pathologist view.- p53 in genetic counseling.- Index.

Blurb

With over 60,000 referenced publications, p53 has emerged as one of the most important factors in human cancer. Research on p53 has led to a complete overhaul of our understanding of the molecular basis of human cancer. In recent years, these major advances in knowledge are starting to impact on cancer management and therapy. This book thus captures a critical turning point in p53 research, from basic to translational research and clinical application.

p53 in the Clinics follows the success of  25 Years of p53 Research and condensates in a series of authoritative chapters the considerable progress on the applications of p53 into the clinics and the substantial advances on diseases caused by inheritance of p53 defects, on somatic p53 mutations as biomarkers in molecular pathology, on progress in gene therapy and on developments of innovative drugs and clinical trials. This volume will appeal to a wide audience of students and professionals in basic and clinical cancer research and treatment, and will highlight the exciting “next steps” in p53 research and applications.